For Healthcare Professionals

A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation

clipboard-pencil

About the study

This is a Phase 3, 2-arm, multicenter study with an open-label ivacaftor arm and an observational arm to evaluate the safety and efficacy of long-term ivacaftor treatment in subjects with cystic fibrosis (CF) who are <24 months of age at treatment initiation and have an approved Ivacaftor-Responsive mutation
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Ivacaftor Arm: Subjects From Study 124 (NCT02725567 ) Part B:

  1. Subjects transitioning from Study 124 Part B must have completed the last study visit of Study 124 Part B.
  2. As judged by the investigator, parent or legal guardian must be able to understand protocol requirements, restrictions, and instructions; and must sign the informed consent form (ICF). Ivacaftor Arm: Subjects Not From Study 124 Part B:
  3. Confirmed diagnosis of CF, or 2 CF-causing mutations.
  4. An ivacaftor
  5. responsive CFTR mutation on at least 1 allele. Subjects will be eligible in countries/regions where ivacaftor is approved for use in subjects 2 years of age and older.
  6. As judged by the investigator, parent or legal guardian must be able to understand protocol requirements, restrictions, and instructions; and must sign the ICF. Observational Arm:
  7. Received ivacaftor treatment in Study 124 Part B and elected not to enroll or ineligible to enroll in the ivacaftor arm of Study 126.

EXCLUSION CRITERIA

Ivacaftor Arm: Subjects From Study 124 Part B:

  1. History of any illness or condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering ivacaftor to the subject.
  2. Subjects receiving commercially available ivacaftor treatment Ivacaftor Arm: Subjects Not From Study 124 Part B:
  3. History of any illness or condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering ivacaftor to the subject
  4. An acute upper or lower respiratory infection, or pulmonary exacerbation, or changes in therapy for pulmonary disease within 4 weeks of Day 1
  5. Abnormal liver function at screening
  6. Hemoglobin <9.5 g/dL at screening
  7. History of solid organ or hematological transplantation
  8. Use of any moderate or strong inducers or inhibitors of CYP3A within 2 weeks of Day 1 Observational Arm:
  9. Receiving ivacaftor treatment Other protocol defined Inclusion/Exclusion criteria may apply.
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall 617-341-6777Email iconEmail Study Center

Study’s details


Contition

Cystic Fibrosis

Age

0+

Phase

Phase 3

Participants needed

86

Est. Completion Date

Jul 2024

Treatment type

Interventional


Sponsor

Vertex Pharmaceuticals Incorporated

ClinicalTrials.gov identifier

NCT03277196

Study number

VX15-770-126

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.